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Objectives: Several investigators have reported decreased expression of
glycoprotein Ib on the platelet surface during coronary artery bypass
grafting, but others could not confirm this finding. Because platelet
glycoprotein Ib functions as an adhesion receptor for von Willebrand factor
and other adhesive proteins, this decreased expression may explain exces-
sive postoperative blood loss. In this study the expressions of glycoprotein
Ib and other platelet activation markers were studied in the systemic and
pericardial blood of seven patients undergoing coronary artery bypass
grafting. Pericardial blood was recently shown to have high activation levels
of fibrinolytic and coagulation pathways; we hypothesized that this local
blood activation might be paralleled by extensive platelet activation and
associated disappearance of glycoprotein Ib. Methods: Expression of plate-
let surface antigens was determined by whole-blood double-label flow
cytometry. Results: Glycoprotein Ib expression in systemic blood decreased
10% (p 5 0.03) from preoperative levels at the start of cardiopulmonary
bypass and 30% (p 5 0.04) before release of the aortic crossclamp.
Expression in pericardial blood at these times decreased by 50% and 51%,
respectively (p 5 0.003, p 5 0.009). No changes were observed in the
expression of the platelet activation antigens CD62P (P-selectin, indicating
platelet a-granular release) and CD63 (indicating lysosomal release) or in
binding of monoclonal antibody PAC-1 (detecting the fibrinogen-binding
receptor conformation of the glycoprotein IIb-IIIa complex). Conclusion:
Glycoprotein Ib disappeared from the platelet surface during bypass
grafting, most notably in pericardial blood. No increased expression of
CD62P, CD63, or PAC-1 was found, indicating the absence of general
platelet activation. (J Thorac Cardiovasc Surg 1998;115:1160-5)
During cardiopulmonary bypass (CPB) the pa-tient’s blood is in extensive contact with the
artificial surface of the extracorporeal circuit. This
contact results in activation of the factor XII–
dependent contact system and thus both the coagu-
lation cascade and the fibrinolytic system.1 Recent
improvements in biocompatibility of the extracorpo-
real circuit, such as the composition of synthetic
materials, membrane oxygenators, and heparin
coatings, have resulted in considerably less blood
activation. Despite these improvements, however,
excessive postoperative blood loss remains one of
the major complications of cardiac operations.2
These bleeding disorders are thought to be caused
at least in part by impairment of platelet function.
Several investigators have demonstrated that the
platelet-specific glycoprotein (GP) Ib, an important
adhesion receptor, disappears from the platelet sur-
face during CPB.3 GPIb is the receptor for von
Willebrand factor, a protein that mediates the inter-
action between platelets and proteins such as colla-
gen in the exposed subendothelium of a damaged
vessel wall.4 A decreased expression of GPIb has
therefore been suggested to lead to a decreased
adhesive capacity and thus to result in prolonged
bleeding and excessive blood loss.2, 5 This hypothesis
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has been confirmed by the finding that administra-
tion of aprotinin, a bovine protein that acts as a
nonselective inhibitor of serine proteases, prevented
the disappearance of GPIb and simultaneously re-
duced the blood loss and the use of blood products
during CPB.6 Several investigators could not dem-
onstrate the disappearance of GPIb, however, and
decreased expression of GPIb in systemic blood
therefore remains under debate.3, 7-10
Boisclair and coworkers11 demonstrated that co-
agulation is initiated during CPB not only by the
contact between blood and the extracorporeal cir-
cuit but also through a tissue factor–factor VII
dependent pathway. More recently, direct evidence
was provided that the expression of tissue factor is
enhanced in the surgical wound and that the extrin-
sic coagulation cascade becomes activated.12 In the
surgical wound, blood oozes from damaged vessels
and makes extensive contact with the damaged
vessel wall and underlying tissues. This blood accu-
mulates in the pericardial cavity, from which it is
removed by suction. Periodically the pericardial
blood is returned into the patient. Thus, whereas
previous studies suggested that blood is activated
predominantly by contact activation, more recent
studies indicate that the contribution of the materi-
al-independent pathway of blood activation—the
operation itself—may be of much greater impor-
tance than previously thought.12, 13 Our aim in this
study was to establish whether the expression of
GPIb is indeed reduced in patients undergoing
coronary artery bypass grafting, whether this is
associated with extensive general platelet activation,
and whether these phenomena are present in both
systemic and, perhaps more considerably, pericar-
dial blood.
Material and methods
Clinical study. This study was approved by the Local
Ethical Committee. After informed consent was obtained,
seven patients undergoing elective coronary artery bypass
grafting entered the study. No patient was older than 85
years or had evidence of severe heart failure, renal or
hepatic dysfunction, or a bleeding diathesis. No patient
was treated with coumarin derivatives, aspirin, dipyridam-
ole, or nonsteroidal antiinflammatory agents within 5 days
before the operation. The study patients did not receive
antifibrinolytic agents or aprotinin during CPB.
CPB and anesthesia. Anesthesia was induced and
maintained with weight-related doses of fentanyl, sufen-
tanil, midazolam, or propofol and pancuronium. The
extracorporeal circuit consisted of a Dideco D704 com-
pact-flow system oxygenator and S3 roller pump (Sto¨ck-
ert, Munich, Germany). The priming of the extracorpo-
real circuit contained lactated Ringer’s solution (1.3 L),
human albumin (200 ml 20% weight/volume), mannitol
(100 ml 20% weight/volume), sodium hydrogen carbonate
(50 ml 8.4% weight/volume), heparin (50 mg), and cefa-
mandol (2 g). Each patient received dexamethasone (1
mg/kg). Volume was corrected with lactated Ringer’s
solution. Heparin (3 mg/kg) was given intravenously be-
fore cannulation of the aorta and repeated in a dose of 50
mg whenever the activated clotting time (Hemochron;
International Technidyne Corp., Edison, N.J.) was shorter
than 480 seconds. Pump flows ranged from 2.0 to 2.4
L/m2/min during hypothermia (28° to 32° C). Myocardial
protection was achieved with modified St. Thomas’ Hos-
pital solution infused in the aortic root. After decannula-
tion heparin was neutralized with protamine sulfate in a
1:1 ratio.
Blood acquisition. All systemic blood samples were
drawn from the same central venous line. The blood
samples from the pericardial cavity were taken directly
from the cavity with a 10 ml syringe. Sampling points were
after induction, before skin incision (sample point 1), 5
minutes after the start of CPB (sample point 2), 10
minutes before release of the aortic crossclamp, at the
start of the last distal anastomosis (sample point 3), and
before protamine administration but after removal of the
atrial canula (sample point 4). Systemic blood samples
were taken at sampling points 1 through 4 and samples
from the pericardial cavity at points 2 through 4. Blood
samples were taken simultaneously at each sampling
point. The hematocrit of systemic blood decreased from
0.33 6 0.02 L/L to 0.25 6 0.05 L/L (sample point 2),
0.22 6 0.03 L/L (sample point 3), and 0.23 6 0.02 L/L
(sample point 4). This decrease resulted from hemodilu-
tion with the priming fluid of the extracorporeal circuit.
The hematocrit of pericardial blood samples decreased to
0.21 6 0.05 L/L (sample point 2), 0.06 6 0.04 L/L (sample
point 3), and 0.20 6 0.03 L/L (sample point 4). The low
hematocrit of pericardial blood at sample point 3 was
caused by hemodilution with saline and cardioplegic so-
lutions. Although the platelet count closely reflected the
changes in hematocrit, this count was not reliable in
pericardial blood at sample point 3 because of the low
platelet number and the presence of high concentrations
of particles or cell fragments, which were erroneously
counted as platelets. However, this artifactually increased
platelet count did not influence the measurement of the
antigen expression on the platelet surface because such
measurements were performed only on the particles with
GPIb expression (platelet material) and the proper for-
ward and sideward light scatter characteristics of the cell
population as assessed by flow cytometry (see the Flow
Cytometric Analysis section).
Monoclonal antibodies. The following monoclonal an-
tibodies were used in this study. Anti-GPIb (CLB-MB45)
was obtained from the Central Laboratory of the Nether-
lands Red Cross Bloodtransfusion Service, Amsterdam,
The Netherlands. The antibody is directed against
GPIb-a. Anti-GPIb was biotinylated as described by
Hnatowich and colleagues.14 Fluorescein isothiocyanate
(FITC)–labeled PAC-1 was provided by Dr. S. J. Shattil,
University of Pennsylvania, Philadelphia. This antibody is
directed against the fibrinogen-binding conformation of
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the activated GPIIb-IIIa complex.15 FITC-labeled anti-
CD63 and FITC-labeled anti-CD62P were obtained from
Immunotech, Marseilles, France. CD63 is present as a
transmembrane protein of lysosomal membranes and is
not found on resting platelets. On platelet activation,
lysosomal membranes fuse with the cell membrane; con-
current with secretion, CD63 appears on the plasma
membrane. CD62P, also called platelet activation–depen-
dent granule-external membrane protein or P-selectin, is a
transmembrane protein of a-granules and is, like CD63,
not present on resting platelets. Like CD63, it appears
concurrently with secretion. Phycoerythrin-conjugated
streptavidin was obtained from Dakopatts, Glostrup,
Denmark.
Flow cytometric analysis. Double-label whole-blood
flow cytometry was performed essentially as described by
Abrams and colleagues15 and Shattil and associates,16
with some modifications. Blood was collected in 0.32%
trisodium citrate (final concentration). Within 5 minutes
after sampling, 5 ml aliquots of blood were added to tubes
containing 30 ml N-2-hydroxyethylpiperazine-N-2-ethane-
sulfonic acid (HEPES) buffer (137 mmol/L sodium chlo-
ride, 2.7 mmol/L potassium chloride, 1.0 mmol/L magne-
sium chloride, 5.6 mmol/L glucose, 20 mmol/L HEPES, 1
mg/ml albumin, 3.3 mmol/L sodium phosphate, pH 7.4), 5
ml anti-GPIb (5 mg/ml final concentration), and, where
indicated, 5 ml of a second FITC-labeled monoclonal
antibody directed against CD62P, CD63, or the fibrino-
gen-binding conformation of the GPIIb-IIIa complex
(monoclonal antibody PAC-1). After 15 minutes of incu-
bation at room temperature in the dark, 5 ml tenfold-
diluted phycoerythrin-conjugated streptavidin was added.
After another 15 minutes of incubation at room temper-
ature in the dark, 2.5 ml HEPES buffer containing 0.2%
paraformaldehyde (weight/volume) was added. No
changes in the expression of surface antigens occurred
within 48 hours after fixation if platelets were prepared
according to this protocol (Berckmans RJ, unpublished
data). To verify our method of platelet activation analysis
by expression of the activation markers, whole blood
obtained from healthy volunteers (n 5 8) and anticoagu-
lated with 0.10 mmol/L sodium citrate (final concentra-
tion) was stimulated with 10 mmol/L adenosine diphos-
phate in vitro. The mean fluorescence intensity (MFI) for
FITC-labeled anti-GPIb decreased from 218 6 20 to
147 6 24, MFI for FITC-labeled anti-CD62P increased
from 3.6 6 0.5 to 10.8 6 4.3, MFI for FITC-labeled
anti-CD63 increased from 5.6 6 0.8 to 9.7 6 1.5, and MFI
for FITC-labeled PAC-1 increased from 11.3 6 4.2 to
79 6 32 (mean 6 standard deviation). These data indicate
that the procedure used to label and fix the platelets can
detect platelet activation by increased antigen expression
of activation markers as well as reduced expression of
GPIb.
The samples were analyzed in a FACScan flow cytom-
eter with PC-lysis software (Becton Dickinson, San Jose,
Calif.). Both forward light scatter and sideward light
scatter were set at logarithmic gain, and platelets were
found in whole blood by analyzing both phycoerythrin-
GPIb fluorescence at 585 nm and light-scattering profile.
The surface expression of activation markers on a popu-
lation of 5000 platelets was determined by the fluores-
cence intensity of the FITC label at 515 nm. The threshold
for platelet activation was set at 2% for CD62P and CD63
and 5% for PAC-1 with the first systemic blood sample of
each patient. The threshold for platelets with reduced
expression of GPIb was arbitrarily set at 10%. Surface
expressions of CD62P, CD63, PAC-1, and GPIb were
compared with those in the first systemic blood sample.
Data are expressed as the percentage of platelets with
decreased (GPIb) or increased (CD62P, CD63, PAC-1)
expression with respect to these arbitrary thresholds. Thus
Fig. 1. Expression of GPIb in systemic blood (open bars) and pericardial blood (hatched bars) during CPB.
A, MFI, as an indicator of the activation status of the total platelet population (n 5 7, mean 6 standard
deviation). B, Percentage of platelets with decreased GPIb expression. The threshold for platelets with
reduced expression was arbitrarily set at 10% for the first systemic blood sample (n 5 7, mean 6 standard
deviation). Significant differences from sample point 1 are represented by asterisk (p , 0.05) and pound sign
(p , 0.01).
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subpopulations of activated platelets may become appar-
ent.17 The data are also expressed as MFI, as an indicator
of the antigen expression of the total platelet population.
Statistical analysis. Comparisons within groups were
assessed with the Wilcoxon signed-rank test and compar-
isons between groups were assessed with the Mann-
Whitney U test with SPSS for Windows version 5.1 (SPSS,
Inc., Chicago, Ill.).
Results
Clinical results. No complications occurred dur-
ing or after the operation. The demographic data
from the patients were as follows: six male patients
and one female patient, mean age 65 years (range 47
to 72 years), mean CPB time 94 minutes (range 45
to 158 minutes), mean aortic crossclamp time 47
minutes (range 21 to 72 minutes), and mean post-
operative blood loss within 24 hours after arrival at
the intensive care unit 907 ml (range 435 to 1865 ml).
Platelet activation analysis. Fig. 1 (A) shows the
expression of GPIb on the platelet surface, as as-
sessed by the MFI, as a measure for the mean
surface antigen density. In systemic blood the MFI
of GPIb decreased by 10% at the start of CPB
(sample point 2; p 5 0.03), 30% before release of
the aortic crossclamp (sample point 3; p 5 0.04),
and 15% at the end of CPB (sample point 4, p 5
0.35). The MFI of GPIb in pericardial blood at
sample point 2 decreased by 50% versus (systemic)
sample point 1 (p 5 0.003), 51% before release of
the aortic crossclamp (sample point 3; p 5 0.009),
and 41% at the end of CPB just before the start of
protamine (sample point 4, p 5 0.05).
To investigate the possibility that the observed
decrease in GPIb expression was mainly caused by
extensive activation of only a subpopulation of the
platelets, the percentage of platelets with reduced
expression of GPIb was measured. The threshold
was arbitrarily set at 10% of the total population
with the first systemic blood sample of each patient.
All subsequent blood samples were compared with
this first blood sample. Fig. 1 (B) shows that the
number of platelets with reduced expression of
GPIb in systemic blood increased from the arbitrary
10% (sample point 1) to 21% (sample point 2; p 5
0.35), 27% (sample point 3; p 5 0.02) and 24%
(sample point 4 ; p 5 0.04). In pericardial blood the
number of platelets with reduced expression of
GPIb increased to 55% (sample point 2; p 5 0.001),
58% (sample point 3; p 5 0.001), and 43% (sample
point 4; p 5 0.001). These findings closely paralleled
the observed decrease in expression of GPIb seen as
MFI, indicating that the decreased MFI is a feature
of the whole platelet population and not of a
subpopulation.
In parallel, the expressions of the activation mark-
ers CD62P, CD63, and PAC-1 were studied (Table
I). To our surprise, no increased expression was
observed, not even in pericardial blood, in which we
had expected platelets to be strongly activated.
Discussion
As in most other studies, we found a decrease in
expression of GPIb in systemic blood (10% to 30%).
In pericardial blood this expression decreased by
approximately 50%. It may seem surprising that we
did not notice a subpopulation of platelets with a
GPIb surface expression reduced by 50% in the
systemic circulation as a result of return of the
pericardial blood during the operation. During our
study, however, which involved routine operations
in patients at low risk, the amount of pericardial
blood returned to the patient was approximately 0.5
L. Because pericardial blood is diluted about ten-
fold, this is comparable to approximately 50 ml
undiluted whole blood. When returned into the
systemic circulation, the number of platelets that
originated from pericardial blood would be 1% of
the total platelet population or less, which is too low
to be accurately detected by flow cytometry. Alter-
natively, the absence of such a subpopulation may
Table I. Expression of CD62P, CD63, and PAC-1 in systemic and pericardial blood
MoAb
Systemic blood Pericardial blood
1 2 3 4 2 3 4
CD62P (MFI) 5.4 6 2.7 8.0 6 9.1 6.1 6 5.5 6.3 6 5.6 4.2 6 1.1 5.0 6 1.9 7.4 6 6.0
CD62P (% act. plt.) 2.0 4.4 6 4.4 2.3 6 1.7 1.7 6 1.6 1.3 6 1.0 3.4 6 4.7 2.3 6 1.6
CD63 (MFI) 7.6 6 3.5 8.7 6 6.5 7.1 6 3.3 8.2 6 6.6 6.4 6 2.4 7.7 6 4.2 9.0 6 8.3
CD63 (% act. plt.) 2.0 2.9 6 1.3 2.1 6 0.9 1.3 6 1.0 1.6 6 0.8 3.6 6 3.8 2.6 6 2.1
PAC-1 (MFI) 12.7 6 9.1 13.4 6 3.0 8.7 6 2.7 8.3 6 3.0 11.9 6 4.6 20.2 6 9.8 8.7 6 4.3
PAC-1 (% act. plt.) 5.0 9.2 6 1.9 10.0 6 5.1 4.0 6 1.4 7.6 6 7.5 8.0 6 4.7 6.0 6 3.2
Data are presented as mean 6 standard deviation. MoAB, Monoclonal antibody; % act. plt., % activated platelets.
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be caused either by adsorption of platelets to the
surface of the extracorporeal circuit or by clearance
by the liver and the reticuloendothelial system.
Conversely, such a small volume of platelets from
the pericardial blood can not cause the reduced
GPIb expression detected on the platelets in the
systemic circulation. This would imply that the
platelets in the circulation also become affected by
nonpericardial processes. In more complicated op-
erations, larger blood volumes are being collected in
the pericardial cavity and returned into the patient;
thus they may become more important for the
overall systemic blood platelet activation analyses.
In this study we incubated the platelets in whole
blood for 30 minutes at room temperature, with the
antibodies added before fixation. Although this
method optimizes the detection of all platelets
present, it may lead to some underestimation of the
GPIb disappearance. Michelson and colleagues18, 19
reported that plasmin and thrombin at 37° C de-
crease GPIb expression as much as 30% to 50% and
20% to 50% of the initial value, respectively. After
inactivation of the plasmin or thrombin, platelets
can replenish their surface GPIb from an intraplate-
let pool as much as 75% to 80% and 70% to 90% of
the initial value, respectively. Still, we chose the
method of antibody incubation before instead of
after fixation because the latter method requires
isolation of the fixed platelets before incubation
with antibodies. This isolation may result in major
loss of platelets, with a high risk of losing subpopu-
lations. In addition, the fixative changes the epitopes
and thus necessitates use of different antibodies.16
The mechanism behind the disappearance of
GPIb remains to be established. For instance,
whether proteolysis of GPIb occurs in whole blood
is unknown, because the in vitro experiments from
Michelson and colleagues18, 19 were performed with
high concentrations of plasmin and washed plate-
lets, in the absence of plasmin inhibitors. Similar
findings were reported for cathepsin G, which re-
duced the expression of GPIb in a washed platelet
system but not in whole blood.20 Compared with
systemic blood, pericardial blood contains relatively
high concentrations of the thrombin–antithrombin
III complex, tissue plasminogen activator, and fibrin
degradation products, indicating that especially in
pericardial blood both thrombin and plasmin are
generated despite anticoagulation with hepa-
rin.12, 13, 21 Whether thrombin, plasmin, or both are
responsible for the disappearance of GPIb in peri-
cardial blood is a subject for further investigation.
The clinical relevance of GPIb disappearance
during CPB remains under debate. To determine
the role of GPIb under flow conditions, we recently
performed experiments with whole blood from
healthy volunteers under flow conditions in which
GPIb had been partially “knocked out” by a mono-
clonal antibody or by internalization after stimula-
tion of the thrombin receptor. As much as 50% to
60% disappearance of GPIb did not affect platelet
adhesion under flow conditions on various sub-
strates, such as collagen type III and von Willebrand
factor.22 These findings are in line with the absence
of bleeding complications in patients heterozygous
for Bernard-Soulier disease and indeed question the
functional consequences of GPIb disappearance for
platelet adherence during CPB in patients at low
risk. On the other hand, because GPIb functions not
only as a platelet adhesion receptor but also as a
high-affinity receptor for thrombin, it is possible that
a partial disappearance of GPIb affects platelet
activation by thrombin.23, 24
In this study no changes were found in expression
of the activation markers CD62P, CD63, and
PAC-1. The absence of an increase in expression of
CD62P may be explained by the subsequent release
of this receptor from the surface of activated plate-
lets, as shown recently by Michelson and cowork-
ers.25 In addition, Santoso and associates26 de-
scribed receptor capping on platelet stimulation in
washed platelets as a result of incubation of unfixed
platelets with specific monoclonal antibodies against
GPIIb-IIIa. We cannot exclude the possibility that
receptor capping also occurs in whole blood; how-
ever, it does not prevent the detection of platelet
activation, as shown by the response of blood from
healthy volunteers on stimulation (see Material and
Methods). On the other hand, the binding of the
monoclonal antibody PAC-1 may be preceded by
binding of fibrinogen, making this GPIIb-IIIa con-
formation inaccessible to PAC-1. At present we do
not have an explanation for the absence of an
increased CD63 expression, except by assuming that
extensive platelet activation with the associated se-
cretory reaction is evidently absent.
Taken together, the data indicate that the GPIb
molecules disappear in part from the platelet sur-
face in the systemic blood, and more notably in the
pericardial blood, without signs of extensive platelet
activation.
We thank Dr. P. G. M. Jansen, Department of Cardiac
Surgery, University Hospital Vrije Universiteit, Amster-
The Journal of Thoracic and
Cardiovascular Surgery
May 1998
1 1 6 4 Maquelin et al.
dam, The Netherlands, clinical epidemiologist and biosta-
tistician, for his statistical advice.
R E F E R E N C E S
1. Edmunds LH Jr. Blood-surface interactions during cardio-
pulmonary bypass. J Card Surg 1993;8:404-10.
2. Woodman RC, Harker LA. Bleeding complications associ-
ated with cardiopulmonary bypass. Blood 1990;76:1680-97.
3. Kondo C, Tanaka K, Takagi K, Shimono T, Shinpo H, Yada
I, et al. Platelet dysfunction during cardiopulmonary bypass
surgery: with special reference to platelet membrane glycop-
roteins. ASAIO J 1993;39:M550-3.
4. Sixma JJ, van Zanten H, Banga JD, Nieuwenhuis HK, de
Groot PG. Platelet adhesion. Semin Hematol 1995;32:89-98.
5. Tabuchi N, de Haan J, Boonstra PW, Huet RC, van Oeveren
W. Aprotinin effect on platelet function and clotting during
cardiopulmonary bypass. Eur J Cardiothorac Surg 1994;8:87-
90.
6. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T.
Aprotinin therapy in cardiac operations: a report on use in 41
cardiac centers in the United Kingdom. Ann Thorac Surg
1993;55:971-6.
7. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault KA,
Smith BR. Modulation of platelet surface adhesion receptors
during cardiopulmonary bypass. Anesthesiology 1991;75:563-
70.
8. Bertolino G, Locatelli A, Noris P, Maurelli M, Ceriana P,
Mazzini G, et al. Platelet composition and function in
patients undergoing cardiopulmonary bypass for heart sur-
gery. Haematologica 1996;81:116-20.
9. Kestin AS, Valeri R, Khuri SF, Loscalzo J, Ellis PA, MacGre-
gor H, et al. The platelet function defect of cardiopulmonary
bypass. Blood 1993;82:107-17.
10. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK.
Comparison of platelet membrane markers for the detection
of platelet activation in vitro and during platelet storage and
cardiopulmonary bypass surgery. J Lab Clin Med 1993;121:
579-87.
11. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S,
Hunt B, et al. Mechanisms of thrombin generation during
surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
12. Chung JH, Gikakis N, Rao K, Drake TA, Colman RW,
Edmunds LH Jr. Pericardial blood activates the extrinsic
coagulation pathway during clinical cardiopulmonary bypass.
Circulation 1996;93:2014-8.
13. de Haan J, Boonstra PW, Monnink SHJ, Ebels T, van
Oeveren W. Retransfusion of suctioned blood during cardio-
pulmonary bypass impairs hemostasis. Ann Thorac Surg
1995;59:901-7.
14. Hnatowich J, Verzin F, Ruscowski M. Investigations of avidin
and biotin for imaging applications. J Nucl Med 1987;28:
1294-302.
15. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct
detection of activated platelets and platelet-derived micro-
particles in humans. Blood 1990;75:128-38.
16. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated
platelets in whole blood using activation-dependent mono-
clonal antibodies and flow cytometry. Blood 1987;70:307-15.
17. Konijnenberg A, Stokkers EW, van der Post JAM, Schaap
MCL, Boer K, Bleker OP, et al. Extensive platelet activation
in preeclampsia compared with normal pregnancy: enhanced
expression of cell adhesion molecules. Am J Obstet Gynecol
1997;176:461-9.
18. Michelson AD, Barnard MR. Plasmin-induced redistribution
of platelet glycoprotein Ib. Blood 1990;76:2005-10.
19. Michelson AD, Benoit SE, Kroll MH, Li JM, Rohrer MJ,
Kestin AS, et al. The activation-induced decrease in the
platelet surface expression of the glycoprotein Ib-IX complex
is reversible. Blood 1994;83:3562-73.
20. Molino M, Di Lallo M, Martelli N, de Gaetano G, Cerletti C.
Effects of leukocyte-derived cathepsin G on platelet mem-
brane glycoprotein Ib-IX and IIb-IIIa complexes: a compar-
ison with thrombin. Blood 1993;82:2442-51.
21. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W.
Activation of fibrinolysis in the pericardial cavity during
cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:
828-33.
22. van Zanten GH, Heijnen HFG, Wu Y, Schut-Hese KM,
Slootweg PJ, de Groot PG, et al. A 50% reduction of platelet
surface glycoprotein Ib does not affect platelet adhesion
under flow conditions. Blood. In press 1998.
23. Greco NJ, Jamieson GA. High and moderate affinity path-
ways for alpha-thrombin-induced platelet activation. Proc
Soc Exp Biol Med 1991;198:792-9.
24. Greco NJ, Tandon NN, Jones GD, Kornhauser R, Jackson B,
Yamamoto N, et al. Contributions of glycoprotein Ib and the
seven transmembrane domain receptor to increases in plate-
let cytoplasmic Ca21 induced by alpha-thrombin. Biochem-
istry 1996;35:906-14.
25. Michelson AD, Barnard MR, Hechtman HB, MacGregor H,
Connolly RJ, Loscalzo J, et al. In vivo tracking of platelets:
circulating degranulated platelets rapidly lose surface P-
selectin but continue to circulate and function. Proc Natl
Acad Sci U S A 1996;93:11877-82.
26. Santoso S, Zimmermann U, Neppert J, Mueller-Eckhardt C.
Receptor patching and capping of platelet membranes in-
duced by monoclonal antibodies. Blood 1986;67:343-9.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 5
Maquelin et al. 1 1 6 5
